Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro

Transplantation

Volumn 71, Issue 10, 2001, Pages 1436-1442

  Wassmuth, Ralf ^a   Hauser, Ingeborg A ^a,c   Schuler, Katja ^a   Erxleben, Harald ^a   Arnold, Marie Luise ^a   Koelman, Carin A ^b   Claas, Frans H J ^b   Kalden, Joachim R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN;

ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HLA TYPING; HUMAN; IMMUNOMODULATION; LYMPHOCYTOTOXICITY; PRIORITY JOURNAL; SENSITIZATION;

EID: 0035958101     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200105270-00014     Document Type: Article

References (33)

1. Comparative effects of pregnancy, transfusion, and prior graft rejection on sensitization and renal transplant results
2. Significance of the positive crossmatch test in kidney transplantation
3. Anti-HLA antibodies following the transplantation of highly sensitised renal allograft recipients
4. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases
5. Mechanisms of action of intravenous immune globulin in immune-mediated diseases
6. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action
7. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg): A potential tool for transplantation of immunized patients
8. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ
9. Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins
10. Additional inhibitory effects of intravenous immunoglobulins in combination with cyclosporine A on human T lymphocyte alloproliferative response in vitro
11. Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin)
12. Decreased alloreactivity after vaccination against hepatitis B
13. Microdroplet assay of human serum cytotoxins
14. Evaluation of dithiothreitol (DTT) for inactivation of IgM antibodies
15. Elevated serum HLA class I levels coincide with acute and chronic graft-versus-host disease
16. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin
17. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII: C inhibitors
18. Polyvalent immunoglobulins in sensitised renal transplant recipients
19. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation
20. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations
21. Complement-immunoglobulin interactions
22. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro
23. Modulation of complement-mediated immune damage by intravenous immune globulin
24. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes
25. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes
26. Inhibition of complement activation by intravenous immunoglobulins
27. A view of the human idiotypic repertoire: Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG
28. Dimeric, trimeric and tetrameric complexes of immunoglobulin G fix complement
29. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases
30. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies
31. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation
32. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection
33. Capillary deposition of C4d complement fragment and early renal graft loss